A
$ Value
$0
Shares
1,316
Price
$0
Filed
Apr 28
Insider
Name
Beckerle Mary C
Title
—
CIK
0001520181
Roles
Director
Transaction Details
Transaction Date
2025-04-24
Code
A
Table
Derivative
Ownership
Direct
Equity Swap
No
Shares After
15,395
Footnotes
Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). | Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person.
Filing Info
Beckerle Mary C's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-02-12 | HUN | A | $0 |
| 2025-11-11 | EXEL | M | $134K |
| 2025-11-11 | EXEL | ▼ | $243K |
| 2025-11-11 | EXEL | ▼ | $789K |
| 2025-11-11 | EXEL | M | $0 |
| 2025-05-29 | EXEL | A | $0 |
| 2025-04-24 | JNJ | A | $0 |
Other Insiders at JNJ (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
REED JOHN C
EVP, Innovative Medicine, R&D
|
— | $13.1M | 2026-02-17 |
|
Duato Joaquin
CEO and Chairman of the Board
|
— | $22.1M | 2026-02-15 |
|
Wolk Joseph J
Exec VP, CFO
|
— | $21.8M | 2026-02-17 |
|
Taubert Jennifer L
EVP, WWC. Innovative Medicine
|
— | — | 2026-02-15 |
|
Wengel Kathryn E
EVP, Chief TO and Risk Officer
|
— | — | 2026-02-15 |
|
Decker Robert J
VP Corporate Controller
|
— | — | 2026-02-15 |
|
Swanson James D.
EVP, CIO
|
— | $15.1M | 2026-02-17 |
|
Broadhurst Vanessa
EVP, Global Corp Affairs
|
— | $1.5M | 2026-02-17 |
|
Forminard Elizabeth
EVP, Chief Legal Officer
|
— | — | 2026-02-15 |
|
Schmid Timothy
EVP, WW Chair, MedTech
|
— | $5.5M | 2026-02-18 |
|
Mulholland Kristen
EVP, Chief HR Officer
|
— | — | 2026-02-15 |